O described that neuroendocrine ductal carcinoma in situ (DCIS) may very well be viewed as a pre-invasive stage of NECB [56]. NeuroendocrineTable 1 Summary of major neuroendocrine carcinoma of the breast situations published within the indexed literature (n=83)aNeuroendocrine IHC Author (year) [Ref] Wade (1983) [18] Jundt (1984) [16] Papotti (1992) [19] Age (years)/Sex 52/F 52/M 64/F 41/F 41/F 69/F Papotti (1993) [17] Francois (1995) [20] Chua (1997) [21] Fukunaga (1998) [22] Samli (2000) [23] Shin (2000) [24] 83/M 68/F 45/F 56/F 60/F 43/F 44/F 46/F 50/F 51/F 57/F 62/F 64/F 70/F Yamasaki (2000) [25] Salmo (2001) [26] Zekioglu (2003) [27] 41/F 46/F 79/F 76/F 65/F 68/F 69/F 72/F 60/F 43/F Web site R R R L L L R R L R L R L R R R L L L L R R R L R R R R R L Size (cm)b 10.0 NS 2.0 three.5 3.0 5.0 1.five four.five NS 10.0 8.0 1.three 2.0 three.four 2.two 1.5 2.5 five.0 1.8 4.0 4.5 four.0 1.five 2.2 three.5 7.0 1.0 1.five 1.0 0.8 TNM T4N1M0 TxN1M0 T1N0M0 T2NxM0 T2NxM0 T3NxM0 T1N0M0 T2N0M0 T2N0Mx T3NxM0 T4N1M0 T1NxM0 T1NxM0 T2NxM0 T2NxM0 T1NxM0 T2NxM0 T3NxM0 T1NxM0 T2NxM0 T2N0M0 T2N0M0 T1N0M0 T2N0M0 T2N0M0 T3N1M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 IS NS + + + + + NS NS + NS NS NS NS + NS NS + NS + + + + + + + + + + + + NS + + + + + + + + + + + + + + + + + + NS + + + + + NS + + + + + + + NS NS NS GML NSE CgA/B Syn NSG + + + + + + + + + + + NS + + NS + + NS + + + + + + Hormonal receptors ER NS NS + NS NS NS NS NS NS NS NS NS NS NS + + + + + + + PR NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS + + + + + + + + HER2/Neu Neoadjuvant NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS Ch Ch NS NS NS NS NS NS NS NS Remedy Surgical Mast/ALND NS Mast/ALND Mast/ALND Mast/ALND Mast/ALND Mast Mast/ALND BCS Mast/ALND Mast/ALND BCS BCS/ALND Mast/ALND BCS/ALND BCS/ALND Mast/ALND Mast/ALND BCS/ALND BCS/ALND BCS/Mast/ALND BCS Mast/ALND BCS Mast/ALND Mast/ALND Mast/ALND BCS BCS BCS Adjuvant Follow-up Outcome (months) Ch Ch/RT NS RT Ch HT NS RT NS Ch/RT RT Ch/RT Ch Ch/HT RT Ch Ch/HT Ch Ch/RT Ch Ch/RT NS NS NS NS NS NS NS NS 9 14 44 15 14 9 84 21 NS 48 six 30 27 11 35 25 ten 32 ten 3 16 9 24 18 16 22 12 13 ten 48 DOD DOD NED DOD LR/DOD DOD DOD D-NOS NS NED LR NED NED AWM NED NED NED AWM NED NED NED NED NED NED NED NED NED NED NED NEDAngarita et al. Planet Journal of Surgical Oncology 2013, 11:128 http://wjso/content/11/1/128 Web page four ofTable 1 Summary of major neuroendocrine carcinoma of the breast circumstances published inside the indexed literature (n=83)a (Continued)60/F 43/F 72/F 72/F Bergman (2004) [28] Bigotti (2004) [29] Jochems (2004) [30] Sridhar (2004) [31] Yamamoto (2004) [32] 61/F 56/F 71/F 58/F 53/F 75/F Berruti (2004) [33] Adegbola (2005) [34] 59/F 46/F 60/F 61/F Valdes (2006) [35] Fujimoto (2007) [36] Kim (2008) [37] Kinoshita (2008) [9] Stita (2009) [38] Yamaguchi (2009) [39] Christie (2010) [40] Latif (2010) [41] Honami (2011) [42] 41/F 40/F 27/F 31/F 64/F 51/F 61/F 53 /F 54/F L L L L L L NS R NS NS NS R R L R/MF L/MF L L L R L R B two.41203-22-9 Chemscene five five.Oxetane-3-carbaldehyde manufacturer 0 two.PMID:33730843 7 2.7 2.five 18.0 3.0 two.0 six.five two.0 NS 1.0 1.7 1.7 1.5 2.0 three.2 6.0 3.0 three.0 three.0 6.0 L: 1.0 R: 1.five Kawanishi (2011) [43] Nozoe (2011) [44] Zhang (2011) [45] 67/F 57/F 29/F R R B 0.8 3.0 L: eight.five R: two.0 Su (2012) [46] Miura (2012) [47] Kawasaki (2012) [48] 75/F 72/F 41/F 45/F 41/F L R/MC L R L four.0 1.5 0.0 0.0 0.0 T2N0M0 T1NxM0 T2NxM0 T1N2M0 T2N0M0 T2N0M0 T2N0M0 T2N0M0 T2NxM0 T3N1M0 T2NxM0 T1NxM0 T3N2M0 T2N1M0 T2N0M0 T1N0M0 T1NxM0 T1NxM0 T1NxM0 T1NxM0 T2NxM0 T3NxM0 T2NxM0 T2NxM0 T2NxM0 T3N0M0 T1N0M0 + + + + + + NS NS NS NS + NS + NS + + NS + + NS + NS L:.